Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells by William N Pappano et al.
Pappano et al. BMC Cancer 2014, 14:430
http://www.biomedcentral.com/1471-2407/14/430RESEARCH ARTICLE Open AccessGenetic inhibition of the atypical kinase Wee1
selectively drives apoptosis of p53 inactive tumor
cells
William N Pappano*†, Qian Zhang†, Lora A Tucker, Chris Tse and Jieyi WangAbstract
Background: Tumorigenesis is the result of genomic or epigenomic insults and subsequent loss of the proper
mechanisms to respond to these alterations leading to unscheduled growth. Tumors arising from these mutations
often have altered cell cycles that offer proliferative advantages and lead to the accumulation of additional
mutations that can lead to more aggressive phenotypes. Nevertheless, tumor cells must still adhere to the basic
tenets of the cell cycle program to ensure their survival by DNA duplication, chromosomal segregation and
cytokinesis. The atypical tyrosine kinase Wee1 plays a key role in regulating the cell cycle at the DNA synthesis and
mitotic checkpoints via phosphorylation and subsequent inactivation of cyclin-dependent kinases (CDKs) in both
healthy and tumorigenic cells.
Methods: To assess the role of Wee1 in tumor cell proliferation we performed small interfering RNA (siRNA)
experiments in a panel of diverse cell lines derived from various tissue origins. We also tested the hypothesis that
any potential effects would be as a result of the kinase activity of Wee1 by siRNA rescue studies with wild-type or
kinase-dead versions of Wee1.
Results: We find that, in general, cells with wild-type p53 activity are not susceptible to loss of Wee1 protein via siRNA.
However, Wee1 siRNA treatment in tumor cells with an inherent loss of p53 activity results in a deregulated cell cycle
that causes simultaneous DNA synthesis and premature mitosis and that these effects are kinase dependent. These
cumulative effects lead to potent inhibition of cellular proliferation and ultimately caspase-dependent apoptosis in the
absence of co-treatment with cytotoxic agents.
Conclusions: These results suggest that, while Wee1 acts as a tumor suppressor in the context of normal cell growth
and its functional loss can be compensated by p53-dependent DNA damage repairing mechanisms, specific inhibition
of Wee1 has deleterious effects on the proliferation and survival of p53 inactive tumors. In total, targeting the atypical
kinase Wee1 with an siRNA-based therapeutic or a selective ATP competitive small molecule inhibitor would be a
feasible approach to targeting p53 inactive tumors in the clinic.
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Proper maintenance of the cell cycle is essential for the
development and homeostasis of all living organisms.
Neoplasms arising within these organisms also rely on a
coordinated cell cycle to facilitate their rapid growth rate
in response to external sources of nutrients and signaling
stimuli. Progression through the cell cycle in both naïve
and tumor tissue is monitored at checkpoints that sense
possible defects in DNA synthesis and chromosomal seg-
regation. Activation of these checkpoints results in cell
cycle arrest and allows cells to rectify any negative pertur-
bations that may be transmitted to their resulting daugh-
ter cells. Tumor cells with defective checkpoints rely more
heavily on other checkpoints within the cell cycle to
ensure their survival. Thus, deregulation of cell cycle con-
trol can have catastrophic results and therefore has led to
a concerted effort towards generation of novel therapeutic
agents targeting the cell cycle in tumors [1].
Transition through the cell cycle is dependent on the
cyclin-dependent kinase (CDK) family of regulatory pro-
teins. CDK activity is tightly monitored through several
complex mechanisms including modulation of CDK sta-
bility by binding partner cyclins and CDK inhibitors [2,3].
However, only a subset of CDK-cyclin complexes are
directly involved in progression of the cell cycle through
these respective checkpoints. The active CDK2-Cyclin E
complex is essential to drive the G1/S transition of the cell
cycle after the restriction checkpoint and the CDK1-Cyclin
B complex (also known as the M-phase-promoting-factor)
is the master regulator that initiates the G2/M transition
after the mitotic checkpoint [4]. In addition to their associ-
ation with cyclins and CDK inhibitors, CDK1 and CDK2
activity are modulated both negatively and positively by
phosphorylation and de-phosphorylation events [4]. Wee1
is an atypical tyrosine kinase that most closely resembles
serine/threonine kinases in both sequence and structure
[5] and acts directly upon CDK1 and CDK2. Wee1 phos-
phorylation of tyrosine 15 (Y15) of CDK1 and CDK2 re-
sults in CDK inactivation and inhibition of S-phase and
mitotic entry [6,7]. Wee1 kinase activity therefore serves
as a master regulator of cell cycle checkpoints by inactiva-
ting the CDK1-Cyclin B and CDK2-Cyclin E complexes
until it can be assured that genomic integrity will be main-
tained and that the appropriate genetic information will be
passed on to daughter cells.
Previous reports of Wee1 inhibition by small molecule
kinase inhibitors and siRNA demonstrate that loss of
Wee1 activity sensitizes p53 inactive cells to DNA dam-
aging agents and radiosensitization [8-12]. We hypothe-
sized that loss of Wee1 in the absence of cytotoxics
should be able to affect tumor cell proliferation because
all metazoan cells, including cancer cells, rely on at least
partially functioning checkpoints to insure their survival.
To elucidate the roles of Wee1 in cancer cell cycleprogression we have utilized siRNA knockdown and res-
cue. We find that loss of Wee1 kinase activity results in
dramatic cell cycle events including simultaneous mitosis
and DNA synthesis that ultimately lead to apoptosis in a
sub-set of p53 deficient cells. The anti-proliferative and
apoptotic effects of Wee1 siRNA treatment can be cir-
cumvented by expression of a wild-type Wee1 rescue con-
struct but not a kinase-defective version in affected target
cells. This work provides new insights into the deve-
lopment of cancer therapeutics, suggesting that a small
molecule inhibitor of Wee1 kinase should be efficacious
against a large number of p53 inactive solid tumors as a
single agent and provide a safe therapeutic window in the
p53 wild-type tissues of patients.
Methods
Cell culture
All cell lines were obtained from ATCC (Manassas, VA,
U.S.A.). All cell lines were grown according to manufac-
turer’s conditions in the presence of fetal bovine serum
(Invitrogen, Carlsbad, CA, U.S.A.).
siRNA oligos and transfection
All siRNAs were obtained from the ON-TARGET plus col-
lection purchased from Dharmacon (Lafayette, CO, U.S.A).
The sense strand sequences of the Wee1 siRNA oligos
employed in the study are as follows: #5 5′-AAUAGAA
CAUCUCGACUUA-3′, #6 5′-AAUAUGAAGUCCCGGU
AUA-3′, #7 5′-GAUCAUAUGCUUAUACAGA-3′, #8 5′-
CGACAGACUCCUCAAGUGA-3′. The negative control
siRNA oligos: NT1 and NT2 product numbers D-001810-
01 and D-001810-02. The Ran oligo targeting sequence was
5′- AGAAGAAUCUUCAGUACUAUU-3′. Transfections
of siRNA duplexes were performed using RNAiMAX re-
agent (Invitrogen).
Cell proliferation and caspase assays
Viable cell numbers were measured using CellTiter-
Glo reagent (Promega, Madison, WI, U.S.A.) or CyQuant
(Invitrogen). Caspase-Glo 3/7 assay (Promega) was used
to measure cellular caspase-3/7 activity.
Antibodies and Western blot analysis
Antibodies used included mouse anti-Wee1, mouse anti-
P53 (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.),
rabbit anti-phospho-CDK1 (Y15), rabbit anti-phospho-
H2AX (S139), mouse anti-phospho-Histone H3 (S10),
rabbit anti-Histone H3 (Cell Signaling Technology, Danvers,
MA, U.S.A.), mouse anti-CDK1 (Millipore, Billerica, MA,
U.S.A.), mouse anti-P21 (BD Biosciences, San Diego,
CA, U.S.A.), and mouse anti-Actin (Sigma, St. Louis,
MO, U.S.A.). Western blots were performed as pre-
viously described [13].
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The human Wee1 coding sequence was amplified using
standard PCR protocols and cloned into the pLVX-puro
lentiviral construct (Clontech, Mountain View, CA, U.S.A.).
Kinase-altered Wee1 (K328R) and siRNA resistant con-
structs were introduced using the QuikChange site directed
mutagenesis kit (Stratgene, Santa Clara, CA, U.S.A.). Cell
lines were generated immediately after infection by mass
selection in 2 μg/ml puromycin (Clontech).
siRNA rescue experiment
Engineered NCI-H1299 cell lines were grown in DMEM
containing 10% fetal bovine serum and 2 μg/ml puro-
mycin. Cell lysate samples were collected 48 hr after
transfection for Western blot analysis. Five days after
siRNA transfection, microscopic cell images were taken
and both floating and attached cells were then collected
by trypsinization and counted for viable cell number
using a Vi-CELL cell viability analyzer (Beckman Coulter,
Brea, CA, U.S.A.).
Time-lapse light microscopy movies
NCI-H1299 and A549 cells were plated and transfected
24 hours later with either control siRNA (NT1) or Wee1
siRNA (#8). Plates were placed in an incubator and im-
ages were captured every 30 minutes using IncuCyte™
High Definition (HD) Imaging (Essen Bioscience, Ann
Arbor, MI, U.S.A). Movies were extracted for the indi-
cated time frames (3 days of siRNA treatment) at a rate
of 10 frames per second.
Analysis of cell cycle by flow cytometry
At varied times after transfection with 5nM siRNA,
adherent cells were trypsinized and combined with any
floating cells present, then washed with cold PBS. Cells
were then stained with 0.5 ml PBS containing 50 μg/ml
propidium iodide (PI), 0.1 mg/ml RNase A, 0.1% BSA,
and 0.1% Triton-X100 for 20 min and cell cycle distribu-
tion was analyzed using a BD LSR-II flow cytometer (BD
Biosciences, San Jose, CA, U.S.A.).
Double thymidine block
H1299 cells were treated with 2 mM thymidine (Sigma)
and blocked for 20 hrs. Cells were then released by
washing with PBS and feeding with regular culture
medium. Four hours after the first release, cells were
transfected with 5nM siRNA and incubated for another
4.5 hrs before the second treatment of 2 mM thymidine.
Cells were blocked with thymidine for another 14.5 hrs
and released again into regular medium. At the second re-
lease (t = 0), cells should be synchronized at G1/S phase
boundary of the cell cycle. Cell samples were collected at
varied time points for cell cycle and Western blot analysis
as described above.Click-iT EdU flow cytometry assay
NCI-H1299 cells were plated in 6-well plate and trans-
fected with 5 nM siRNA as described above. After 24 or
48 hr incubation, cells were labeled with 10 μM EdU
(Invitrogen) for 30 min. Both floating and attached cells
were then collected for fixation, Click-iT reaction, and
cell cycle staining following manufacturer’s protocol.
Cell samples were analyzed for DNA content and EdU
level using BD LSR-II flow cytometer.
Results
Wee1 siRNA treatment results in potent inhibition of
proliferation in a subset of human solid tumor cell lines
Previous published reports on Wee1 inhibition by small
molecule intervention or siRNA knockdown provide con-
flicting results regarding whether the loss of Wee1 kinase
activity can result in the inhibition of growth in tumor cell
lines [8,10-12,14]. To test the hypothesis that ablation of
Wee1 in the absence of cytotoxics would have effects on
cellular health we performed siRNA experiments on a
panel of human cell lines derived from solid tumors of di-
verse origin. Four distinct siRNAs targeting Wee1 as well
as negative (non-targeting siRNA #1 and #2) and positive
(Ran, [15]) controls were added to cells for the duration of
the experiments. The negative controls ensure that siRNA
transfection has no deleterious effects on cell growth
while the positive control provides a reference of ma-
ximum cell killing possible and ensures transfection effi-
ciency. The resulting phenotypes of Wee1 siRNA resulted
in dramatic inhibition of cellular proliferation as measured
by MTS reagent in H1299 non-small cell lung (NSCLC)
and Daoy glioma cell lines but did not affect growth of
A549 NSCLC, D54MG glioma or A2780 ovarian tumor
lines (Figure 1). Similar results were obtained using DNA
content (CyQuant assay) as a measure of proliferation
(Additional file 1).
The striking differences between responding and non-
responding tumor cell lines to Wee1 siRNA could not be
easily explained by off-target effects because of the com-
plete lack of efficacy in A549, D54MG and A2780 cells.
However, one possible explanation for the mixed pheno-
typic effects of Wee1 siRNAs was differential loss of the
Wee1 protein. To explore this possibility, we performed
Western blot analysis of all five cell lines after siRNA
transfection to assess the loss of Wee1 protein. We also
examined pCDK which served as a biomarker readout for
loss of Wee1 activity in these cells. siRNA treatment re-
sulted in a roughly equivalent loss of Wee1 protein from
effective siRNAs in all cell lines examined (Figure 2 and
Additional file 2). Moreover, the loss of Wee1 kinase acti-
vity also appeared to be roughly equivalent in each of the
tumor cell lines based on the levels of CDK Y15 phos-
phorylation (Figure 2 and Additional file 2). The siRNAs
targeting Wee1 used in this study produced protein
Figure 1 Wee1 knockdown results in potent inhibition of
proliferation in a subset of human tumor cell lines. (a-e) NCI-H1299,
A549, Daoy, D54MG and A2780 cell lines were subjected to 5 nM siRNA
treatment for five days following plating and end-point analysis was
performed using CellTiter-Glo . Controls included no siRNA (No),
non-targeting siRNAs (NT1 and NT2) as negative controls and Ran
siRNA (Ran) as a positive control for transfection efficiency. Four
individual Wee1 siRNAs were used (#5-#8). Percent inhibition was
calculated using the negative control (No siRNA) as 0% inhibition and
the positive control (Ran siRNA) as 100% inhibition to control for
relative transfection in each individual cell line. Results represent
triplicate counts from a representative experiment with error bars
representing s.e.m.
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nanomolar concentrations in all cell lines analyzed (data
for Daoy cells shown in Additional file 3). It should be
noted that the peptide-based pCDK monoclonal antibody
that is used in this study and others cannot distinguish
between CDK1, CDK2 and CDK5 phosphorylation as each
of these kinases have identical peptides in the region
surrounding the Y15 phosphorylation site. In total, these
results indicate that differential loss of Wee1 protein or
kinase activity amongst cell lines is not the cause of the
dramatic differences seen in cellular phenotypes after
Wee1 siRNA treatment. These data indicate that in a
number of cancer cell lines Wee1 is absolutely essential
for survival.
Wee1 siRNA treatment is on-target and its effects are
kinase activity dependent
We performed siRNA rescue experiments to rule out
the possibility of off-target effects leading to the inhi-
bition of proliferation seen after Wee1 siRNA treatment
in the subset of cell lines we assayed. To accomplish this
goal, stable NCI-H1299 NSCLC cell lines with a vec-
tor control or a siRNA-resistant version of Wee1 were
isolated and subjected to siRNA treatment for both pro-
liferation and Western blot analyses. The Wee1 siRNA-
resistant DNA construct had scrambled seed regions for
both siRNAs #6 and #8 but still coded for the WT amino
acid sequence of Wee1. Our results indicate that, while
the vector control cell line responded phenotypically
(proliferation) and molecularly (Western) as expected,
the siRNA-resistant Wee1 cells were unaffected by treat-
ment (Figure 3a–j). These results confirm that the
siRNAs targeting Wee1 are on-target and that the dra-
matic cellular changes are solely a result of the loss of
Wee1 protein.
Using these experimental methods we could also deter-
mine if the siRNA effects were a result of loss of a scaf-
folding function or kinase activity of Wee1. To answer
this question, we generated a siRNA-resistant/kinase-
altered version of Wee1 in which altering the critical ac-
tive site lysine of Wee1 to an arginine residue (K328R)
Figure 2 Wee1 siRNA treatment produces efficient target knockdown in all cell lines assayed. NCI-H1299, A549, Daoy and D54MG cells
were subjected to 5 nM siRNA treatment for two days following plating. Non targeting siRNA (N1) and Wee1 siRNAs #5-#8 were all analyzed.
Direct cell lysates were analyzed by Western blotting to ascertain loss of Wee1 protein levels as well as the effects on its direct target (pCDK).
pCDK Western samples were spliced between H1299 and A549 to provide exposure times that result in similar levels of visible phosphorylation
for all cell lines. Total CDK1 and Actin were blotted to control for total protein levels.
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H1299 cells over-expressing the siRNA-resistant/kinase-
altered version of Wee1 were not rescued to a similar
extent as the kinase-active version (Figure 3f–o). The
siRNA-resistant/kinase altered Wee1 construct does pro-
duce a slight amount of phenotypic rescue (~35%) for
both siRNA #6 and #8, but this can be explained by one of
two likely possibilities: the K328R change may not pro-
duce a fully kinase-dead Wee1 or the over-expressed
siRNA-resistant Wee1 constructs may cause some degree
of siRNA protection to the endogenous Wee1 mRNA
present in the cells. These effects can be seen on the mo-
lecular level when relative levels of phospho- to total-CDK
(p/t CDK) are taken into account. The level of p/t CDK is
essentially absent in the vector control NCI-H1299 cells
(Figure 3e), restored in the siRNA-resistant cells (Figure 3j)
and partial when the siRNA-resistant/kinase altered Wee1
is over-expressed (Figure 3o). These experimental results
imply that the Wee1 siRNAs are on-target and that the
loss of kinase activity and the subsequent downstream sig-
naling effects are responsible for the dramatic effects of
Wee1 siRNA treatment on cellular proliferation seen in a
specific subset of solid tumor cell lines.
Wee1 knockdown effects are stronger in tumor cell lines
with recognized inactive p53 status
Having ruled out several plausible explanations for the
drastically different phenotypic response to Wee1 siRNA
treatment in our initial 5 cell lines we decided to expand
the number of cell lines in our study. We added 15 more
tumor cell lines for a total of 20 from various tissue
origins and found that, in general, response to Wee1
siRNA treatment correlated well with inactive p53 status
(Table 1). The trend in sensitivity upon Wee1 knock-
down towards inactive p53 status can be observed when
comparing wild-type p53 tumor cell lines (top 7 cell
lines with an average 76% viability) to tumor cell lineswith deletion/nonsense mutations and the E6 virus that
result in cell lines with recognized inactive p53 status
(bottom 6 cell lines with an average of 12.5% viability).
Direct evidence for the importance of p53 status in
response to loss of Wee1 activity
The observed effects of Wee1 inhibition and their ap-
parent relation to p53 status presented herein and else-
where [8,12] suggested that abrogation of p53 in a
normally p53 wild-type setting would generate sensitivity
to Wee1 inhibition. To directly test this hypothesis we
performed experiments in isogenic pairs of the colo-
rectal carcinoma cell line RKO over-expressing either a
vector control or the human papillomavirus protein E6.
E6 expression is associated with a substantial decrease in
p53 protein levels in these cells resulting in a clonal cell
line with inactive p53 [18]. We performed siRNA experi-
ments and found dramatic inhibition of proliferation in
the RKO-E6 cells treated with Wee1 siRNAs while the
RKO-vector cells were unperturbed (Figure 4a). Western
blot analyses revealed that Wee1 protein knockdown
and subsequent loss of cellular activity as shown by
pCDK levels were roughly equivalent in both cell lines
although there was a marked difference in the levels of
p53 protein and its transcriptional target p21 in the two
cell lines (Figure 4b).
Loss of Wee1 activity results in caspase-dependent
apoptosis in p53-null cells
In an attempt to decipher the potential mechanisms by
which Wee1 ablation affects cell growth, we performed
caspase-activity assays after Wee1 siRNA treatment.
Wee1 siRNAs resulted in an induction of Caspase 3/7
activity in a time-dependent fashion in NCI-H1299 and
Daoy cells but did not affect A549, D54MG and A2780
cells (Figure 5). These effects correspond well to the cel-
lular proliferation data seen in Figure 1 and suggest that
Figure 3 Wee1 knockdown by siRNA treatment is specific and
its effects are kinase dependent. NCI-H1299 vector control cells
were treated with no siRNA (a), non-targeting siRNA (N1) (b), Wee1 #6
(c) or Wee1 #8 (d) siRNAs for five days. The remaining percentage of
viable cells after proliferation is given for each sample. (e) NCI-H1299
vector control cells were subjected to 5 nM siRNA treatment for two
days following plating and analyzed by Western blot to determine
effects on Wee1 knockdown and pCDK levels. The ratio of phospho/total
CDK (p/t CDK) resulting from each siRNA treatment was determined
by densitometry relative to their Actin controls. (f-i) NCI-H1299 cells
over-expressing a wild type Wee1 with siRNA resistant seed regions. The
samples are the same as in a-e. (k-o) NCI-H1299 cells over-expressing
a kinase-altered Wee1 K328R with siRNA resistant seed regions. The
samples are the same as in a-e. All results are representative of three
separate experiments.
Table 1 Wee1 siRNA effects on cell line panel
Cell line Cancer origin TP53 status % viability
A2780 Ovary WT 98
A549 Lung WT 102
D54MG Glioma WT 93
HCT-116 Colon WT 74
MCF-7 Breast WT 65
U87MG Glioblastoma WT 42
ZR-75-1 Breast WT 57
U118MG Glioblastoma R213Q 73
HCT-15 Colon S241F 98
DLD-1 Colon S241F 89
DAOY Medulloblastoma C242F 3
MiaPaca-2 Pancreas R248W 92
A431 Epidermis R273H 70
MDA-MB-231 Breast R280K 15
MDA-MB-453 Breast 368-del30 29
MDA-MB-361 Breast S166* 5
Calu-6 Lung R196* 7
HeLa Cervix Low (E6) 3
SK-N-MC Ewing’s −/− 27
H1299 Lung −/− 4
Efficacy of Wee1 siRNA treatment was assayed in a panel of 20 solid human
cell lines derived from various tumors. Percent viability is measured after five
days by taking the average of Wee1 siRNAs #6 and #8 and comparing them to
the non-targeting and Ran siRNA controls. p53 genotype data were procured
from The p53 Mutation HandBook (http://p53.free.fr [17]). All results are the
average of a minimum of three separate experiments.
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rather than inhibition of proliferation from cytostatic
effects. This caspase-dependent apoptosis is rescued in
cells over-expressing the siRNA-resistant Wee1 con-
struct (data not shown). Additionally, the likely cell-
cycle related effects of Wee1 knockdown resulted in
activation of caspase activity at a slower rate than the
positive control Ran siRNA. For example, when compa-
ring the Caspase-3/7 activity at 48 and 72 hours it
should be noted that effects of Ran siRNA in cells peaksat 48 hours and decreases in most cell lines by 72 hours,
presumably because most cells have already undergone
apoptosis. However, Wee1 knockdown has a slower rate
of caspase induction that begins at ~ 48 hours and re-
mains steady at 72 hours (Figure 5 and data not shown).
Loss of Wee1 activity has dramatic cell cycle effects in a
subset of tumor cell lines
The timing of caspase activity induction and the known
functions of Wee1 at both the mitotic and DNA syn-
thesis checkpoints suggested that cell death in sensitive
lines was related to cell cycle control. To interrogate this
possibility, we performed propidium iodide (PI) DNA
staining of cells and performed flow cytometry at time
points after Wee1 siRNA treatment. A549, D54MG and
A2780 cells had unperturbed cell cycles after Wee1
knockdown that were indistinguishable from a non-
targeting siRNA control at 24, 48 and 72 hours after
treatment (Figure 6 and data not shown). However, two
cell lines with impaired p53 activity, NCI-H1299 and
Daoy, had significant cell cycle effects after Wee1 knock-
down as compared to the non-targeting siRNA con-
trol at all time points analyzed (Figure 6 and data not
Figure 4 Loss of Wee1 protein affects only the isogenic RKO inactivated p53 cell line. (a) RKO-vector control (gray bars) and RKO-E6
(black bars) cell lines were subjected to 5 nM siRNA treatment for five days following plating. (b) RKO-vector control and RKO-E6 cell lines were
subjected to 5 nM siRNA treatment for two days following plating. Direct cell lysates were analyzed by Western blotting to ascertain loss of Wee1
protein levels as well as the effects on its direct target (pCDK). p53 and p21 protein levels were assessed to determine effects of the HPV-E6
transgene. Total CDK1 and Actin were blotted to control for total protein levels.
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resulted in a substantial accumulation of DNA content
greater than 2 N that corresponded to a mixture of
S-phase, G2/M and >4 N DNA content in cells that ulti-
mately led to a significant fraction of sub-G1 DNA con-
tent corresponding with cell death that peaks at 48 hours
post-transfection (Figure 6). We also visualized NCI-
H1299 and A549 cells by live cell imaging after transfec-
tion with Wee1 and controls siRNAs (Additional files 4, 5,
6 and 7) and found that the A549 cells treated with con-
trol and Wee1 siRNAs were indistinguishable in pheno-
type and growth rates. However, NCI-H1299 cells treated
with Wee1 siRNA appear to start and abort mitosis
at more rapid time periods than their respective non-
targeting siRNA control counterparts as visualized by
cellular shape changes from flat to round [19]. The cumu-
lative results shown in Figure 6 and the time-lapse light
microscopy movies suggest that NCI-H1299 and Daoy
cellular DNA content may be undergoing concomitant
attempts to perform DNA synthesis and mitosis leading
to aneuploidy and incomplete DNA synthesis and this
ultimately leads to apoptotic cell death after treatment
with Wee1 siRNA.
Loss of Wee1 activity results in mistimed cell cycle events
Cell populations can be synchronized at specific stages of
the cell cycle through various means including serum star-
vation and chemical methods. However, several of these
methods are harsh and not amenable to co-treatment with
siRNA because of the length of time required for turnover
of endogenous protein levels to decrease. We found that
Wee1 siRNA treatment resulted in optimal loss of Wee1
protein at 16 hours post-transfection (data not shown).
With this timing limitation in mind, we decided upon
double thymidine block to synchronize cells in late
G1/early S-phase because of its relative lack of toxicity
coupled with the length of treatment. NCI-H1299 cellstreated with non-targeting or Wee1 siRNAs were also
subjected to synchronization and analyzed for DNA con-
tent and Western blot at time points following thymidine
block release. The cells treated with control siRNA pro-
ceeded through the cell cycle from the S-phase block to
G2/M and back to G1 as expected, but the cells without
Wee1 activity never make it past S-phase and eventually
die (Figure 7a). Of particular interest is that cells treated
with Wee1 siRNA already have the mitotic marker
phospho-Histone H3 (pHH3) present at the release point
(t = 0 h) as seen by Western blot analysis (Figure 7b). This
demonstrates that despite the lack of G2 DNA content in
these cells that they still enter M-phase. This results in
DNA damage that is again visible at the release from thy-
midine block in Wee1 knockdown cells as seen by the in-
creased signal of the rapid response DNA damage marker
γ-H2AX (Figure 7b). The gross phenotype of NCI-H1299
cells without functional Wee1 at 24 hours after thymidine
release also suggests an abnormal percentage of cells in a
“rounded” mitotic state (Figure 7c).
Wee1 knockdown results in incorrect timing of DNA
replication origin firing
To look more closely at the non-mitotic effects resulting
from the loss of Wee1 kinase activity, we performed EdU
incorporation assays in both A549 and NCI-H1299 cells.
We transfected Wee1 siRNA and a non-targeting siRNA
control and performed dual Edu and DNA content flow
cytometry on cells at 24 and 48 hours after treatment
(Figure 8). In this assay, A549 cells treated with either
siRNA had G1 DNA content that could incorporate EdU
until a DNA content of 4 N is reached corresponding to
the G2/M stage of the cell cycle indicating the lack of pre-
mature mitosis in these cells. NCI-H1299 cells with Wee1
knocked down continued to accumulate DNA content
(>4 N) while still trying to add more DNA as seen by in-
corporation of EdU (Figure 8). These results are reflective
Figure 5 Wee1 knockdown results in caspase-dependent
apoptosis in a subset of solid tumor cell lines. (a) NCI-H1299,
(b) A549, (c) Daoy, (d) D54MG and (e) A2780 cells were subjected
to siRNA treatment for 48 (gray bars) or 72 hours (black bars) and
assayed for induction of Caspase-3/7 using the Caspase-Glo 3/7
assay. Results shown indicate fold induction of Caspase-3/7 activity.
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in U2OS cells resulting in increased activity of both CDK1
and CDK2 kinase activity [14].
Discussion
Wee1 is a master regulator of cellular integrity and its
activity keeps normal cells from proceeding through the
S-phase and G2/M checkpoints before their genomic
content is adequately prepared to do so [6,7]. We found
Wee1 to be over-expressed in a number of solid primary
tumors (data not shown, www.oncomine.com) and this
has recently been demonstrated in primary gliobla-
stomas [10]. These data suggest that Wee1 may play a
role in some cancer cells to maintain a level of genetic sta-
bility to enable the growth advantage conferred by their
new cancer karyotype. We hypothesized that cancer cells
would be susceptible to loss of Wee1 kinase activity based
on the premise that all metazoan cells, including those in
neoplasms, rely on the correct timing of cell cycle events
for their survival and proliferation. Our studies indicate
that this hypothesis is correct in a subset of solid tumor
cell lines with inactive p53. Upon loss of Wee1 kinase
activity resulting from specific siRNA knockdown, these
cells undergo DNA synthesis while attempting simultan-
eous mitosis, ultimately leading to mitotic catastrophe and
caspase-dependent apoptosis.
p53 is a short-lived transcription factor that acts as
a tumor suppressor to detect and eliminate incipient
cancerous cells. p53 activity results from a complex
network involving the DNA damage response, trans-
criptional activation and post-translational modifications
and results in regulation of hundreds of genes [20].
Neutralization of p53 function is a major hallmark of
tumor cells and this loss can be the result of direct
somatic mutation, deletion, proteasomal degradation or
sequestration to achieve a pathologic survival advantage
[21]. One such protein that mediates degradation of p53
that we have utilized in this study is the human papil-
lomavirus protein E6. In addition to the numerous
methods to hinder p53 activity mentioned above, ana-
lyzing p53 function in cells is further complicated by the
genetic redundancy inherent to cells in the form of the
other members of the p53 gene family, TP63 and TP73
[22]. As a result, loss of p53 activity is difficult to
categorize by simple direct genotyping methods of TP53.
This can be best witnessed within our cell line panel
data in response to Wee1 knockdown. While there
Figure 6 Wee1 knockdown causes dramatic cell cycle effects cell cycle in a subset of solid tumor lines. Cells were subjected to 5nM non-
targeting (N1) or Wee1 siRNAs (#6 and #8) and stained with PI for FACS analysis. NCI-H1299 cells were analyzed for DNA content at 24, 48 and
72 hours after siRNA transfection. DNA content of A549, Daoy, D54MG and A2780 cells were analyzed at 72 hours after siRNA transfection.
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http://www.biomedcentral.com/1471-2407/14/430certainly appears to be a trend towards TP53 status,
there are exceptions to this rule including the U87MG
and MCF-7 WT p53 cell lines. To attempt to avoid
some of the inherent complexities of the p53 tumor sup-
pressor pathway, we focused our study on cell lines that
have well characterized p53 activity in the literature, in-
cluding the p53 null NCI-H1299 and p53 WT A549 cell
lines, as well as the isogenic RKO pair of cell lines.
Therefore, we can only conclude from our studies that,in general, there is a susceptibility of p53 inactive cells
to respond to Wee1 knockdown.
Previous studies have linked p53 status to cellular
sensitivity to loss of Wee1 by siRNA or small molecule
inhibitors but always in the presence of cytotoxic agents
[8,10-12,14]. The proposed hypothesis for this mechan-
ism is that cells with inactive p53 have a defective G1/S
checkpoint and therefore can be sensitized to inhibition
of the G2/M checkpoint in combination with DNA-
Figure 7 Wee1 siRNA treatment results in mistimed cell cycle events in NCI-H1299 cells. (a) NCI-H1299 cells were synchronized in S-phase
using double thymidine block and treated with non-targeting (N1) or Wee1 (#8) siRNAs. DNA content was measured by FACS analysis of PI staining
of cells at 0, 4, 8 and 24 hours after release. (b) NCI-H1299 cells were treated as in (a) and directly lysed and analyzed by Western blotting at 0 and
32 hours after release. (c) NCI-H1299 cells were treated as in (a) and representative light microscopy phenotypic images were captured 24 hours
after release.
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that specific loss of Wee1 kinase activity results in inhi-
bition of proliferation and apoptosis in a subset of solid
tumor cell lines in the absence of co-treatment with
cytotoxic agents. Therefore, a highly specific small mol-
ecule inhibitor targeting only the cell cycle suppressor
Wee1 should kill p53 inactive tumor cells in the absence
of cytotoxic treatment. It should be noted that, while
p53 status is difficult to ascertain due to its complexity,
most normal tissues would have a functioning p53
tumor suppressor pathway.
Our findings reveal that Wee1 inhibition affects both
the G1/S and G2/M transitions through the cell cycle.
Wee1 is capable of inactivating both the CDK2-CyclinE
and CDK2-CyclinB complexes [6,7] and the Y15 specificFigure 8 Loss of Wee1 activity results in incorrect initiation of
DNA synthesis in NCI-H1299 cells but not A549 cells. NCI-H1299
and A549 cells were treated with 5 nM non-targeting (N1) or Wee1 (#8)
siRNAs and stained for DNA content (X-axis) and EdU incorporation
(Y-axis) to mark cells in S-phase. Samples were taken at both 24 and
48 hours after treatment.antibody used in this study and others is identical in both
CDK1 and CDK2. Therefore, loss of Y15 phosphorylation
seen after Wee1 siRNA knockdown may correspond to
either or both of these cyclin dependent kinases. We have
presented data consistent with the hallmarks of activation
of both of these kinases including phospho-Histone H3
upregulation (CDK1) and DNA synthesis marked both by
DNA content > 4 N as well as continued incorporation of
EdU into cells with higher DNA content (CDK2). It
should be noted that we did not observe similar effects
upon siRNA knockdown of the other members of the
DNA damage response including CHK1/2 and the related
CDK regulatory threonine kinase Myt1 (data not shown).
It appears therefore that Wee1 acts as the major regula-
tory kinase in the control of the G1/S and G2/M check-
points. This is likely because of its direct proximity in the
DNA damage response to the CDKs and the importance
of the Y15 site over the T14 site phosphorylated by Myt1.
Conclusions
In this study we demonstrate that loss of Wee1 protein re-
sults in dramatic cell cycle events, including mitotic catas-
trophe and mistimed DNA synthesis, ultimately resulting
in caspase-dependent apoptosis in a subset of p53 inactive
cells. We have achieved this by using siRNA knockdown
and provided evidence that this knockdown is specific and
kinase dependent through siRNA rescue studies. One
compelling finding of this study that will require further
analyses is how the subset of p53 active cells are able to
accommodate the loss of Wee1 activity and proceed
through the cell cycle and proliferate at an equivalent rate
to the no siRNA and non-targeting siRNA controls. We
postulate loss of Wee1 results in activation of the DNA
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http://www.biomedcentral.com/1471-2407/14/430damage responses and that p53 inactive cells cannot re-
balance CDK activities and ultimately have cell cycle mis-
timing and die via apoptosis. In conclusion, we believe
that these data have important ramifications for the treat-
ment of malignancies, and a renewed effort to identify
highly specific small molecule inhibitor of Wee1 could
provide an unmet clinical need in the treatment of solid
tumors.
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Additional file 1: Proliferation results upon Wee1 knockdown are
similar using both metabolic and DNA content readouts. NCI-H1299
(a) and A549 (b) cells treated with non-targeting (N1), Wee1 (#8) and Ran
siRNAs at both 5 and 20 nM for five days measured for viability using
MTS reagent. NCI-H1299 (c) and A549 (d) cells treated with non-targeting
(N1), Wee1 (#8) and Ran siRNAs at both 5 and 20 nM for five days
measured for DNA content using CyQuant reagent.
Additional file 2: Wee1 siRNA treatment produces efficient target
knockdown in A2780 cells. A2780 cells were subjected to 5 nM siRNA
treatment for two days following plating. Non-targeting siRNA (N1) and
Wee1 siRNAs #5-#8 were all analyzed. Direct cell lysates were analyzed by
Western blotting to ascertain loss of Wee1 protein levels as well as the
effects on its direct target (pCDK). Total CDK1 and Actin were blotted to
control for total protein levels.
Additional file 3: Wee1 siRNA treatment is effective over a
wide-range of concentrations. Daoy cells were subjected to 0.2, 1, 5
and 20 nM siRNA treatment for two days following plating. Direct cell
lysates were analyzed by Western blotting to ascertain loss of Wee1
protein levels as well as the effects on its direct target (pCDK). Total CDK1
and Actin were blotted to control for total protein levels.
Additional file 4: NCI-H1299 cells transfected with control (NT1)
siRNA.
Additional file 5: NCI-H1299 cells transfected with Wee1 (#8) siRNA.
Additional file 6: A549 cells transfected with control (NT1) siRNA.
Additional file 7: A549 cells transfected with Wee1 (#8) siRNA.
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